About: Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients
Creator	Corsi, Martina Foiadelli, Thomas Orsini, Alessandro Peroni, Diego Riva, Antonella Santangelo, Andrea Savasta, Salvatore Striano, Pasquale
Source	Medline; PMC
abstract	COVID-19 is a pandemic caused by human coronavirus (HCoV) SARS-CoV-2, which originated in Wuhan, China, at the end of 2019 and spread globally during 2020. Due to the difficulty of clinical decision-making during this period, our study group reviewed current literature focusing on the neurological and psychiatric aspects of COVID-19. Despite the knowledge on this newly discovered virus which is constantly evolving, different pieces of evidence reported an association between COVID-19 and neurological symptoms like headache, dizziness, taste and smell disorders and complications involving the nervous system eventually triggered by the pathologic processes elicited by SARS-CoV-2. It seems that younger patients are less prone to develop severe forms of COVID-19. However, neurological signs have been reported in paediatric patients as well, and in some cases, the infection presented neurological sequelae. Furthermore, children with particular neurological diseases or treated with specific drugs (e.g. immune-suppressant therapies) must be carefully monitored during this pandemic. Neurologists should be aware of the main drug–drug interactions and the neurological side effects of COVID-19 treatments. Notably, adverse mental health impact has been reported in patients with SARS-CoV-2, which could be related either to the social strain or to the eventual neurotropic effects of the virus, which in other infections have been proven to promote the onset of psychiatric symptoms. Further, psychiatric population may be more vulnerable to the infection and at higher risk for adverse outcomes.
has issue date	2020-08-06(xsd:dateTime)
bibo:doi	10.1007/s10072-020-04544-w
bibo:pmid	32767055
has license	no-cc
sha1sum (hex)	7808ec7332ad540eefb4d33826764e46c1dd63c0
schema:url	https://doi.org/10.1007/s10072-020-04544-w
resource representing a document's title	Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients
has PubMed Central identifier	PMC7410516
has PubMed identifier	32767055
schema:publication	Neurol Sci
resource representing a document's body	covid:7808ec7332ad540eefb4d33826764e46c1dd63c0#body_text
is schema:about of	named entity 'neurological' named entity 'globally' named entity '2019' named entity 'psychiatric' named entity 'evolving' named entity 'sequelae' named entity 'neurological' named entity 'virus' named entity 'infection' named entity 'outcomes' named entity 'human' named entity 'pathologic' named entity 'specific' named entity 'population' named entity 'neurotropic' named entity 'therapies' named entity 'treated' named entity 'Neurologists' named entity 'neurological' named entity 'COVID-19' named entity 'COVID-19.' named entity 'SARS-CoV-2' named entity 'Wuhan' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'decision-making' named entity 'neurological' named entity 'infection' named entity 'COVID-19' named entity 'Germany' named entity 'virus' named entity 'meningeal' named entity 'SARS-CoV-2' named entity 'Europe' named entity 'psychiatric treatment' named entity 'comorbidities' named entity 'mechanical ventilation' named entity 'CoV' named entity 'viral genome' named entity 'encephalopathy' named entity 'CNS' named entity 'hydroxychloroquine' named entity 'COVID-19' named entity 'IST' named entity 'SARS-CoV-2' named entity 'daily living' named entity 'CNS' named entity 'electrophysiological' named entity 'COVID-19' named entity 'inoculation' named entity 'respiratory failure' named entity 'clinical trials' named entity 'D-dimer' named entity 'cytokine storms' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'randomized trial' named entity 'neuron' named entity 'inflammatory response' named entity 'tumour necrosis factor-alpha' named entity 'CNS' named entity 'SARS-CoV-2' named entity 'inflammatory response' named entity 'COVID' named entity 'paediatric' named entity 'COVID-19' named entity 'Coronaviridae' named entity 'pulmonary injury' named entity 'ICU delirium' named entity 'pathologies' named entity '5.4' named entity 'CSF' named entity 'CSF' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software